Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Pain-Related Fear and Motor Control in Healthy Volunteers (Domokiss)

6 luglio 2026 aggiornato da: Adrien Nourry, Universite de Picardie Jules Verne

Understanding the Interaction Between Pain-Related Fear and Motor Control: Manipulating Movement-Related Threat in Healthy Volunteers

The goal of this clinical trial is to learn how experimentally induced movement-related threat affects emotional, autonomic, and motor responses in healthy adults. The main questions it aims to answer are:

  • Does movement-related threat change walking performance or upper-limb pointing movements?
  • Are these effects moderated by participants' level of kinesiophobia?
  • Does movement-related threat increase apprehension or alter heart rate variability responses?

Participants will complete two experimental conditions during one session: a control condition and an experimental condition. In both conditions, inactive transcutaneous electrical nerve stimulation (TENS) electrodes will be placed in the lumbar region. In the experimental condition, participants will receive verbal suggestions about discomfort, movement-evoked pain, and potential unpredictable electrical stimulation to create the threat of pain associated with movement. Participants will complete a baseline assessment of kinesiophobia, followed by walking and pointing tasks, while perceived apprehension and autonomic responses are assessed.

Panoramica dello studio

Descrizione dettagliata

In the presence of pain, individuals often modify the way they move. However, pain-related motor adaptations cannot be understood solely as responses to nociceptive input, as pain is shaped by a complex interplay of individual and contextual factors. As a result, motor behavior may be influenced not only by pain itself, but also by the anticipation that movement could be painful or harmful, thereby becoming a perceived threat. Within the fear-avoidance framework, fear of movement and pain-related threat are considered important factors influencing motor behavior and autonomic responses. As pain-related apprehension and kinesiophobia may also be present in pain-free individuals, experimental paradigms inducing movement-related threat in healthy participants may help clarify the mechanisms underlying behavioral adaptations associated with pain-related fear and kinesiophobia.

The main objective of this study, which was concealed from participants, was to determine how movement-related threat influences motor behavior. Specifically, the study assessed whether a verbally induced threat affects walking parameters and upper-limb pointing movement time. A secondary objective was to examine whether baseline trait kinesiophobia moderates the effects of movement-related threat on motor behavior.

This study uses a randomized within-subject crossover design to investigate the effects of experimentally induced movement-related threat on motor responses, perceived apprehension, and autonomic responses in healthy adults. Participants complete two experimental conditions during a single experimental session: a control condition and an experimental threat condition. In both conditions, inactive transcutaneous electrical nerve stimulation electrodes are placed in the lumbar region. In the control condition, electrodes are presented as safe and reliable, without any threat-related information. In the experimental condition, participants receive verbal suggestions regarding discomfort, movement-evoked pain, and unpredictable electrical stimulation associated with the device, in order to induce movement-related apprehension.

Motor behavior is evaluated through spatiotemporal gait parameters during walking and movement time during upper-limb pointing movements toward visual targets. Autonomic nervous system responses are assessed using heart rate and heart rate variability analysis from a wearable heart rate monitor. Perceived apprehension is assessed using visual analog scales. Baseline trait kinesiophobia is assessed at the beginning of the session and used as a continuous variable in the analyses.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

26

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Loos, Francia, 59120
        • Eurasport

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

Sì

Descrizione

Inclusion Criteria:

  • Age between 18 and 65 years.
  • Ability to understand the experimental instructions and questionnaires.
  • No pain at inclusion and during the last 3 months.
  • Abstinence from short-term analgesics for 2 hours before testing.
  • Abstinence from coffee and cigarette smoking for 6 hours before testing.

Exclusion Criteria:

  • History of chronic pain.
  • Motor, neurological, or sensory disorders.
  • Cardiovascular conditions likely to affect physiological measurements.
  • Clinically significant depressive symptoms or anxiety scores on the Hospital Anxiety and Depression Scale.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore fittizio: Control electrodes
Participants were exposed to control electrodes described as safe and reliable, without threat-related information. Participants then completed autonomic, walking, and pointing assessments.
Control condition using verbal suggestions about the safety and reliability of electrodes placed in the lumbar region and associated with an inactive transcutaneous electrical nerve stimulation device. No threat-related information regarding discomfort, movement-evoked pain, or unpredictable electrical stimulation was provided. The condition aimed to assess motor and autonomic responses during motor tasks under neutral instructions.
Sperimentale: Experimental electrodes
Participants were exposed to experimental electrodes associated with verbal information suggesting discomfort, movement-evoked pain, and unpredictable electrical stimulation during movement. The transcutaneous electrical nerve stimulation device was inactive but emitted a sound to reinforce the threat manipulation. Participants then completed autonomic, walking, and pointing assessments.
Experimental induction of movement-related threat using verbal suggestions about potential discomfort and movement-evoked pain associated with electrodes placed in the lumbar region, as well as unpredictable electrical stimulation from an inactive transcutaneous electrical nerve stimulation device. The manipulation aimed to increase movement-related apprehension and anxiety during motor tasks.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Difference in walking speed between the control electrode and experimental electrode conditions
Lasso di tempo: Day 1, during the walking task under each randomized electrode condition
Walking speed will be assessed during the walking task using the GAITRite electronic walkway system. Walking speed will be expressed in meters per second and compared between the control and experimental electrode conditions.
Day 1, during the walking task under each randomized electrode condition
Difference in walking cadence between the control electrode and experimental electrode conditions
Lasso di tempo: Day 1, during the walking task under each randomized electrode condition
Walking cadence will be assessed during the walking task using the GAITRite electronic walkway system. Walking cadence will be expressed in steps per minute and compared between the control and experimental electrode conditions.
Day 1, during the walking task under each randomized electrode condition
Difference in walking stride length between the control electrode and experimental electrode conditions
Lasso di tempo: Day 1, during the walking task under each randomized electrode condition
Walking stride length will be assessed during the walking task using the GAITRite electronic walkway system. Walking stride length will be expressed in meters and compared between the control and experimental electrode conditions.
Day 1, during the walking task under each randomized electrode condition
Difference in upper-limb pointing movement time between the control electrode and experimental electrode conditions
Lasso di tempo: Day 1, during the upper-limb pointing task under each randomized electrode condition
Upper-limb pointing movement time will be assessed during the pointing task using a custom Arduino-based device. Movement time will correspond to the interval between finger lift-off from the starting position and contact with the illuminated target, and will be expressed in milliseconds. Movement time will be assessed across four target locations: ipsilateral 80%, ipsilateral 110%, contralateral 80%, and contralateral 110% of arm length. Movement time will be compared between the control and experimental electrode conditions.
Day 1, during the upper-limb pointing task under each randomized electrode condition

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Kinesiophobia
Lasso di tempo: Baseline
Kinesiophobia will be assessed using the French-Canadian version of the Tampa Scale for Kinesiophobia (TSK-CF). It is a 17-item self-report questionnaire using a Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree). The total score is obtained by adding the item scores and ranges from 17 to 68. A score of 37 out of 68 is considered the threshold at which kinesiophobia becomes significant.
Baseline
Change from Baseline in heart rate variability
Lasso di tempo: Day 1: baseline, during the control electrode condition, and during the experimental electrode condition
Heart rate variability (HRV) will be assessed as an index of autonomic nervous system activity. Intervals between successive R waves (R-R intervals) will be continuously recorded throughout the single assessment session, starting with the baseline resting period and continuing through the control and experimental electrode conditions. The root mean square of successive differences (RMSSD) will be derived from the continuous recording to evaluate autonomic responses associated with pain anticipation.
Day 1: baseline, during the control electrode condition, and during the experimental electrode condition
Change from baseline in perceived apprehension
Lasso di tempo: Day 1: baseline, during the control electrode condition, and during the experimental electrode condition
Perceived apprehension related to the experimental context will be assessed using a 0-10 visual analogue scale, where 0 indicates "no apprehension at all" and 10 indicates "the highest apprehension imaginable." Participants will rate their apprehension in order to evaluate changes in apprehension associated with the experimental instructions and procedures.
Day 1: baseline, during the control electrode condition, and during the experimental electrode condition

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Brief Pain Inventory
Lasso di tempo: Baseline
Current pain status will be assessed using the Brief Pain Inventory, French version (BPI-FR), a self-report questionnaire widely used to evaluate pain severity and pain-related interference with daily activities. In this study, the BPI-FR is used to confirm the absence of clinically relevant pain at inclusion. The questionnaire includes 11 items: four items assessing pain intensity and seven items assessing the extent to which pain interferes with daily functioning, mood, sleep, and social activities. Pain intensity and interference are rated on numeric scales ranging from 0 (no pain or no interference) to 10 (worst imaginable pain or complete interference). Higher scores indicate greater pain severity and impact.
Baseline

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

3 novembre 2025

Completamento primario (Effettivo)

6 luglio 2026

Completamento dello studio (Effettivo)

6 luglio 2026

Date di iscrizione allo studio

Primo inviato

21 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

3 giugno 2026

Primo Inserito (Effettivo)

9 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be publicly shared.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi